

Supplementary Online Content

Tomasello G, Petrelli F, Ghidini M, Russo A, Passalacqua R, Barni S. FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis. *JAMA Oncol*. Published online May 25, 2017.
doi:10.1001/jamaoncol.2017.0278

eTable. Characteristics of Included Studies and Efficacy of FOLFOXIRI-Bevacizumab

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable. Characteristics of Included Studies and Efficacy of FOLFOXIRI-Bevacizumab

Author/year	Type of study/ median follow up (months)	N° pts/ median age (years)	Treatment arm	Unresectable/LLD (%)	Median n° cycles	ORR % (n° events/n° pts)	Median OS (months)	Median PFS (months)	Resection rate % (n° events/n° pts)	R0 % (n° events/n° pts)	Quality of evidence (Jadad/NOS)
Bendell/2016	Randomized phase II/NR	93*/57.5	FOLFOXIRI- bevacizumab	100/30	-	72 (67/93)	-	11.7	15 (14/93)	15 (14/93)	3
Cheng/2015	Retrospective/27	69*/NR	**FOLFOXIRI- bevacizumab	100/37.6	11	71 (49/69)	31,3	13,5	-	16 (11/69)	6 (NOS)
Gruenberger/2015	Randomized phase II/NR	41*/63	FOLFOXIRI- bevacizumab	100/100	-	81 (33/41)	-	18.6	61 (25/41)	49 (20/41)	3
Ichikawa/2014	Phase I-II/NR	16/NR	FOLFOXIRI- bevacizumab	-/100	-	51 (8/16)	-	-	64.2 (9/16)	64.2 (9/16)	5 (NOS)
Loupakis/2014	Phase II/25.7	15/56	FOLFOXIRI- bevacizumab	100/46.6	10	60 (9/15)	24.1	9.2	-	16 (1/7 with LLD only)	7 (NOS)
Cremolini/2015	Phase III/48.1	252*/60	FOLFOXIRI- bevacizumab	100/18	11	65.1 (164/252)	29.8	12.3	-	15 (38/252)	4
Masi/2010	Phase II/28.8	57/61	FOLFOXIRI- bevacizumab	100/53	12	77 (44/57)	30.9	10	32 (18/32)	26 (15/57)	8 (NOS)
Shimada/2015	Retrospective/NR	12/NR	NR	100/100	-	-	-	-	64 (7/12)	64 (7/12)	5 (NOS)
Stein/2015	Prospective/15	97/58	FOLFOXIRI- bevacizumab	100/38.8	12	65 (63/97)	32.2	11.1	27 (26/97)	18 (17/97)	7 (NOS)
Falcone/2016	Randomized phase II/25.7	117*/61	FOLFOXIRI- bevacizumab → bev maintenance	100/27	-	68 (80/117)	-	9.5	53°	-	3
Schmoll/2016	Randomized phase II/NR	120*/61#	FOLFOXIRI- bevacizumab	-/-	-	75 (90/120)	27.9	12	26 (31/120)	-	3

*, only FOLFOXIRI-Bevacizumab arm considered; FA, folinic acid; °, liver-limited disease only patients; #, median age of both arms; LLD, liver-limited disease; OS, overall survival; PFS, progression-free survival; NOS, Nottingham-Ottawa Scale; NR, not reported; d, day; R0, radical resection; OXA, oxaliplatin; CPT11, irinotecan; FU, 5-Fluorouracil; **, 5-Fluorouracil 200-400 mg/m²/2400 bolus/continuous infusion day 1+ oxaliplatin 85 mg/m² day 1 + irinotecan 150 mg/m² day 1 + bevacizumab 5 mg/kg day 1 every 14 days; FOLFOXIRI + bevacizumab, 5-Fluorouracil 200/3200 mg/m² bolus/continuous infusion day 1+ oxaliplatin 85 mg/m² day 1 + irinotecan 160 mg/m² day 1 + bevacizumab 5 mg/kg day 1 every 14 days;